Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions
Z Megyesfalvi, CM Gay, H Popper… - CA: a cancer journal …, 2023 - Wiley Online Library
Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …
Small-cell lung cancer
CM Rudin, E Brambilla, C Faivre-Finn… - Nature Reviews Disease …, 2021 - nature.com
Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …
[HTML][HTML] Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer
Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined
by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A,-N, and-P …
by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A,-N, and-P …
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Small cell lung cancer (SCLC) is an exceptionally lethal malignancy for which more effective
therapies are urgently needed. Several lines of evidence, from SCLC primary human …
therapies are urgently needed. Several lines of evidence, from SCLC primary human …
[HTML][HTML] A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization …
The classification of neuroendocrine neoplasms (NENs) differs between organ systems and
currently causes considerable confusion. A uniform classification framework for NENs at any …
currently causes considerable confusion. A uniform classification framework for NENs at any …
[HTML][HTML] First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
L Horn, AS Mansfield, A Szczęsna… - … England Journal of …, 2018 - Mass Medical Soc
Background Enhancing tumor-specific T-cell immunity by inhibiting programmed death
ligand 1 (PD-L1)–programmed death 1 (PD-1) signaling has shown promise in the treatment …
ligand 1 (PD-L1)–programmed death 1 (PD-1) signaling has shown promise in the treatment …
Lineage plasticity in cancer: a shared pathway of therapeutic resistance
Lineage plasticity, the ability of cells to transition from one committed developmental
pathway to another, has been proposed as a source of intratumoural heterogeneity and of …
pathway to another, has been proposed as a source of intratumoural heterogeneity and of …
[HTML][HTML] MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate
Small cell lung cancer (SCLC) is a neuroendocrine tumor treated clinically as a single
disease with poor outcomes. Distinct SCLC molecular subtypes have been defined based …
disease with poor outcomes. Distinct SCLC molecular subtypes have been defined based …
[HTML][HTML] Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer
Durable responses and encouraging survival have been demonstrated with immune
checkpoint inhibitors in small-cell lung cancer (SCLC), but predictive markers are unknown …
checkpoint inhibitors in small-cell lung cancer (SCLC), but predictive markers are unknown …
Emerging strategies for the treatment of small cell lung cancer: a review
WJ Petty, L Paz-Ares - JAMA oncology, 2023 - jamanetwork.com
Importance Small cell lung cancer (SCLC) is an aggressive disease that is characterized by
rapid growth and the early development of metastases. Patients typically respond to initial …
rapid growth and the early development of metastases. Patients typically respond to initial …